ONCY
$1.16
Oncolytics Biotech
$.02
1.75%
ONCY
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.28)
Revenue:  N/A
Tuesday
Feb 11
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ONCY reports earnings?
Beat
Meet
Miss

Where is ONCY's stock price going from here?
Up
Flat
Down
Stock chart of ONCY
Analysts
Summary of analysts' recommendations for ONCY
Score
Grade
Pivots
Resistance
$1.42
$1.35
$1.25

$1.18

Support
$1.08
$1.01
$0.91
Tweet
Growth
Description
Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsInterCeptVertex PharmaceuticalsJohnson & JohnsonZoetisBristol-Myers SquibbEndo International plcMylanUltragenyx Pharmaceutical